

CITATION REPORT

List of articles citing

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

DOI: 10.1016/j.ccr.2008.01.034
Cancer Cell, 2008, 13, 206-20.

Source: <https://exaly.com/paper-pdf/43775342/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
979	Modes of resistance to anti-angiogenic therapy. 2008 , 8, 592-603		2271
978	The role of myeloid cells in the promotion of tumour angiogenesis. 2008 , 8, 618-31		1224
977	A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. <i>Cancer Cell</i> , 2008 , 13, 181-3	24.3	73
976	Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. <i>Cancer Cell</i> , 2008 , 14, 299-311	24.3	215
975	Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. <i>Cancer Cell</i> , 2008 , 14, 408-19	24.3	606
974	Novel anti-angiogenic therapies for malignant gliomas. 2008 , 7, 1152-60		183
973	Antiangiogenic therapy in brain tumors. 2008 , 8, 1457-73		51
972	Neural stem cell tropism to glioma: critical role of tumor hypoxia. 2008 , 6, 1819-29		143
971	Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. 2008 , 1, 155-67; discussion 165		155
970	Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. <i>Drug Resistance Updates</i> , 2008 , 11, 219-30	23.2	93
969	Modulation of the "blood-tumor" barrier improves immunotherapy. 2008 , 7, 2452-5		25
968	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. 2008 , 105, 16254-9		40
967	Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. 2008 , 68, 9788-98		250
966	Chapter 3. Bone marrow-derived vascular progenitors and proangiogenic monocytes in tumors. 2008 , 445, 53-82		3
965	Inflammation and stem cells in gastrointestinal carcinogenesis. 2008 , 23, 350-9		50
964	Tumor growth-promoting properties of macrophage migration inhibitory factor. 2008 , 14, 3790-801		60
963	Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. 2008 , 21, 736-44		45

962	TRANSLATIONAL IMPACT. 2008 , 1, 165-165	78
961	Antiangiogenic therapy in malignant gliomas. 2008 , 20, 652-61	38
960	Retinal endothelial cell apoptosis stimulates recruitment of endothelial progenitor cells. 2009 , 50, 4967-73	20
959	Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. 2009 , 4, e5947	81
958	Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. 2009 , 284, 25854-66	92
957	Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. 2009 , 106, 17910-5	365
956	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. 2009 , 69, 6889-98	120
955	Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. 2009 , 106, 19485-90	204
954	Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. 2009 , 284, 1765-71	68
953	AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. 2009 , 11, 260-73	76
952	White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. 2009 , 69, 5259-66	242
951	Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. 2009 , 73, 1200-6	253
950	Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells. 2009 , 15, 365-79	50
949	Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. 2009 , 8, 970-6	30
948	Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. 2009 , 18, 1549-57	43
947	Hypoxia helps glioma to fight therapy. 2009 , 9, 381-90	86
946	Inhibition of intracranial glioma growth by endometrial regenerative cells. 2009 , 8, 606-10	43
945	Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. 2009 , 106, 2353-8	249

944	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. 2009 , 15, 5020-5		231
943	Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. 2009 , 2, 330-7		31
942	Angiogenesis as a therapeutic target in malignant gliomas. 2009 , 14, 621-36		87
941	Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. 2009 , 15, 3265-76		121
940	Modulation of g protein signaling normalizes tumor vessels. 2009 , 69, 396-9		22
939	The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. <i>Seminars in Cancer Biology</i> , 2009 , 19, 111-5	12.7	59
938	Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. <i>Seminars in Cancer Biology</i> , 2009 , 19, 338-43	12.7	52
937	Drug resistance associated with antiangiogenesis therapy. <i>Seminars in Cancer Biology</i> , 2009 , 19, 310-7	12.7	52
936	Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. 2009 , 9, 444		143
935	VEGFR2+PDGFRbeta+ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI). 2009 , 13, 3720-9		13
934	Tumor-associated macrophages: effectors of angiogenesis and tumor progression. 2009 , 1796, 11-8		179
933	Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy?. 2009 , 1796, 5-10		33
932	Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. 2009 , 1796, 41-9		7
931	Metastasis mechanisms. 2009 , 1796, 293-308		230
930	Nitric oxide causes macrophage migration via the HIF-1-stimulated small GTPases Cdc42 and Rac1. 2009 , 47, 741-9		33
929	Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. <i>Cancer Cell</i> , 2009 , 15, 35-44	24.3	916
928	Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. <i>Cancer Cell</i> , 2009 , 15, 220-31	24.3	1941
927	Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. 2009 , 18 Suppl 3, S41-7		30

926	Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. 2009 , 125, 1054-64	84
925	Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. 2009 , 60, 2926-34	78
924	Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. 2009 , 12, 159-64	96
923	Antiangiogenic strategies for treatment of malignant gliomas. 2009 , 6, 513-26	30
922	Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. 2009 , 92, 317-35	228
921	Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia. 2009 , 94, 173-81	16
920	Tumor initiating cells in malignant gliomas: biology and implications for therapy. 2009 , 87, 363-74	67
919	Circulating osteogenic precursor cells in heterotopic bone formation. 2009 , 27, 2209-19	90
918	Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. 2009 , 69, 1460-9	85
917	Why is effective treatment of asthma so difficult? An integrated systems biology hypothesis of asthma. 2009 , 87, 601-5	7
916	Nonischemic cerebral venous hypertension promotes a pro-angiogenic stage through HIF-1 downstream genes and leukocyte-derived MMP-9. 2009 , 29, 1482-90	26
915	Kaplan et al. reply. 2009 , 461, E5-E5	2
914	Cancer: The nuances of therapy. 2009 , 458, 290-2	47
913	The metastatic niche: adapting the foreign soil. 2009 , 9, 285-93	939
912	New advances that enable identification of glioblastoma recurrence. 2009 , 6, 648-57	114
911	Biology of angiogenesis and invasion in glioma. 2009 , 6, 447-57	160
910	Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model. 2009 , 75, 854-61	11
909	Regulation of angiogenesis by oxygen and metabolism. 2009 , 16, 167-79	293

908	Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. 2009 , 45, 1117-1128	71
907	The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. 2009 , 15, 333-43	83
906	Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. 2009 , 30, 1073-81	1908
905	Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. 2009 , 27, 489-97	36
904	Antiangiogenic therapies for high-grade glioma. 2009 , 5, 610-20	204
903	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. 2009 , 7, 49	47
902	Stem cells in gastroenterology and hepatology. 2009 , 6, 724-37	91
901	Mechanisms of Brain Tumor Angiogenesis. 2009 , 461-506	
900	Tumor angiogenesis in melanoma. 2009 , 23, 431-46, vii-viii	21
899	Insights into pharmacotherapy of malignant glioma in adults. 2009 , 10, 2279-90	4
898	VEGFR1-activity-independent metastasis formation. 2009 , 461, E4; discussion E5	62
897	Cochlear pericyte responses to acoustic trauma and the involvement of hypoxia-inducible factor-1alpha and vascular endothelial growth factor. 2009 , 174, 1692-704	55
896	Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. 2009 , 175, 1638-52	48
895	VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. 2009 , 6, 229-36	146
894	Corrupt policemen: inflammatory cells promote tumor angiogenesis. 2009 , 21, 60-70	88
893	Bone marrow-derived cells and epithelial tumours: more than just an inflammatory relationship. 2009 , 21, 77-82	22
892	Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. 2009 , 64, 819-26; discussion 826-7	28
891	Current world literature. 2009 , 21, 83-96	

890	Signaling mechanisms in infantile hemangioma. 2009 , 16, 202-8	35
889	A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. 2009 , 114, 901-14	278
888	CEACAM1+ myeloid cells control angiogenesis in inflammation. 2009 , 113, 6726-36	42
887	Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. 2009 , 114, 1987-98	35
886	Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. 2009 , 16, 269-73	74
885	TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy. 2010 , 10, 374-80	34
884	Monocytes: subsets, origins, fates and functions. 2010 , 17, 53-9	188
883	Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer. 2010 , 16, 220-5	4
882	.	
881	Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding. 2010 , 17, 245-51	73
880	Premetastatic Niches. 2010 , 161-182	
879	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. 2010 , 45, 794-807	50
878	Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications. 2010 , 120, 17-24	26
877	TGFbeta and cancer metastasis: an inflammation link. 2010 , 29, 263-71	48
876	American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA. 2010 , 99, 297-306	2
875	Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole. 2010 , 10, 143	39
874	Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. 2010 , 1803, 103-20	171
873	Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. 2010 , 25, 1701-6	42

872	12-O-tetradecanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKC α /ERK/NF-kappaB-dependent MMP-9 expression. <i>Journal of Cellular Physiology</i> , 2010 , 225, 472-81	7	78
871	F1000 highlights. 2010 , 6, vi-vii		
870	PHD2 in tumour angiogenesis. <i>British Journal of Cancer</i> , 2010 , 103, 1-5	8.7	51
869	Glioblastoma stem-like cells give rise to tumour endothelium. 2010 , 468, 829-33		940
868	VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. 2010 , 17, 499-512		130
867	Circulating osteogenic precursor cells. 2010 , 20, 171-80		14
866	. 2010 ,		1
865	Blood-based biomarkers for the optimization of anti-angiogenic therapies. <i>Cancers</i> , 2010 , 2, 1027-39	6.6	1
864	Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. 2010 , 2010, 201026		121
863	Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. 2010 , 2010, 412985		46
862	Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. 2010 , 2010, 251231		65
861	Progress on antiangiogenic therapy for patients with malignant glioma. 2010 , 2010, 689018		34
860	Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. 2010 , 5, e8611		27
859	Adipose tissue-derived progenitor cells and cancer. 2010 , 2, 103-13		74
858	Immunoregulatory cells of the tumor microenvironment. 2010 , 15, 291-308		6
857	Place des antiangiogéniques dans la prise en charge des cancers colorectaux métastatiques. 2010 ,		
856	The perivascular niche microenvironment in brain tumor progression. 2010 , 9, 3012-21		118
855	Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. 2010 , 12, 233-42		399

854	Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. 2010 , 9, 1361-70	46
853	Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. 2010 , 16, 848-56	30
852	Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. 2010 , 70, 2213-23	187
851	Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. 2010 , 16, 924-35	48
850	Knockout of HIF-1 β in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. 2010 , 31, 1863-72	114
849	Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. 2010 , 86, 236-42	368
848	Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. 2010 , 107, 15553-8	210
847	Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. 2010 , 70, 1534-43	134
846	HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. 2010 , 14, 1047-57	52
845	From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. 2010 , 30, 2331-6	54
844	Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. 2010 , 8, 459-70	48
843	Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. 2010 , 16, 4809-21	59
842	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. 2010 , 28, 193-201	123
841	Hypoxia and metastasis in breast cancer. 2010 , 345, 121-39	25
840	Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. 2010 , 107, 8363-8	275
839	Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. 2010 , 107, 2497-502	136
838	Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. 2010 , 70, 5270-80	238
837	Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma. 2010 , 70, 10131-40	42

836	Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. 2010 , 70, 2224-34	145
835	Regulation of monocyte subset systemic levels by distinct chemokine receptors controls post-ischaemic neovascularization. 2010 , 88, 186-95	54
834	Ultrastructural characterization of macrophage-like mononuclear leukocytes in human astrocytic tumors. 2010 , 34, 321-6	2
833	Pathological angiogenesis facilitates tumor cell dissemination and metastasis. 2010 , 9, 913-7	47
832	Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF. 2010 , 9, 743-8	17
831	Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. 2010 , 70, 5679-85	225
830	Heterogeneity of the tumor vasculature. 2010 , 36, 321-31	250
829	Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors. 2010 , 10, 593-600	1
828	Oxygen sensing: a common crossroad in cancer and neurodegeneration. 2010 , 345, 71-103	19
827	[Advances in adults' gliomas biology, imaging and treatment]. 2010 , 97, 17-36	12
826	Endothelial progenitor cells: hope beyond controversy. 2010 , 10, 914-21	13
825	Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. 2010 , 70, 6139-49	264
824	Endothelial progenitor cells and spleen: new insights in regeneration medicine. 2010 , 12, 7-16	5
823	Glioma stem cell signaling: therapeutic opportunities and challenges. 2010 , 10, 709-22	30
822	Hypoxic tumors and their effect on immune cells and cancer therapy. 2010 , 651, 1-29	34
821	Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. 2010 , 16, 122-32	61
820	Drug or vaccine?: selecting the appropriate treatment for malignant glioma patients. 2010 , 70, 1477-86	3
819	Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. 2010 , 16, 3420-30	282

818	Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. 2010 , 12, 87-94	62
817	Hypoxia-inducible factors and the response to hypoxic stress. 2010 , 40, 294-309	1554
816	TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. 2010 , 31, 220-7	618
815	Tumors as organs: complex tissues that interface with the entire organism. 2010 , 18, 884-901	827
814	Mechanisms of resistance to antiangiogenesis therapy. 2010 , 46, 1323-32	124
813	Mediator subunits: gene expression pattern, a novel transcript identification and nuclear localization in human endothelial progenitor cells. 2010 , 1799, 487-95	18
812	Macrophage diversity enhances tumor progression and metastasis. 2010 , 141, 39-51	3150
811	Matrix metalloproteinases: regulators of the tumor microenvironment. 2010 , 141, 52-67	3358
810	Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications. 2010 , 126, 371-81	25
809	Molecular pathways and targets in cancer-related inflammation. 2010 , 42, 161-70	144
808	Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. 2010 , 37, 423-30	65
807	Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. 2010 , 176, 496-503	74
806	Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. 2010 , 176, 1564-76	123
805	Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. 2010 , 176, 2958-71	223
804	Is there really a yin and yang to VEGF-targeted therapies?. 2010 , 11, 809-11	17
803	Glioblastoma. 2010 ,	1
802	Immunotherapy of Cancer. 2010 ,	1
801	The Tumor Microenvironment. 2010 ,	4

800	Diverse Effects of Hypoxia on Tumor Progression. 2010 ,	5
799	CXCR2-Dependent Endothelial Progenitor Cell Mobilization in Pancreatic Cancer Growth. 2011 , 4, 20-8	31
798	Transforming growth factor- β in the gastrointestinal and hepatic tumor microenvironment. 2011 , 141, 1167-78	141
797	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. 2011 , 8, 210-21	534
796	Role of Tumour-Associated Macrophages in the Regulation of Angiogenesis. 2011 , 17-29	1
795	Hypoxia-inducible factor-1 β s essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. 2011 , 20, 1961-71	78
794	C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. 2011 , 108, 302-7	73
793	Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. 2011 , 179, 1455-70	214
792	Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. 2011 , 21, 193-215	1657
791	Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. 2011 , 309, 145-50	27
790	Aberrant PGE $_2$ metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. 2011 , 11, 848-55	30
789	VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. 2011 , 17, 347-62	334
788	Blockade of vascular endothelial growth factor sensitizes tumor-associated vasculatures to angiolytic therapy with a high-frequency ultrashort pulsed laser. 2011 , 82, 141-6	8
787	Macrophage regulation of tumor angiogenesis: implications for cancer therapy. 2011 , 32, 123-45	127
786	Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma. 2011 , 59, 1060-75	10
785	Vascular targeting of adipose tissue as an anti-obesity approach. 2011 , 32, 300-7	64
784	Tumor angiogenesis: molecular pathways and therapeutic targets. 2011 , 17, 1359-70	1274
783	Blood-brain barrier integrity and breast cancer metastasis to the brain. 2010 , 2011, 920509	50

782	Angiogenic signaling aberrantly induced by tumor hypoxia. 2011 , 16, 31-48	42
781	Extracellular Matrix Microenvironment in Glioma Progression. 2011 ,	15
780	A concerted HIF-1 α /MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells. 2011 , 6, e21511	28
779	SDF-1 α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. 2011 , 9, 1462-70	27
778	The role of chemokines, cytokines and adhesion molecules in stem cell trafficking and homing. 2011 , 17, 3271-9	20
777	Lack of angiogenesis in experimental brain metastases. 2011 , 70, 979-91	34
776	Bone marrow mesenchymal stem cells in a three-dimensional gelatin sponge scaffold attenuate inflammation, promote angiogenesis, and reduce cavity formation in experimental spinal cord injury. 2011 , 20, 1881-99	109
775	The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. 2011 , 117, 88-97	228
774	Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. 2011 , 117, 3485-93	101
773	Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence. 2011 , 117, 4142-53	66
772	A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. 2011 , 9, 414-27	95
771	Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. 2011 , 30, 54-64	74
770	Molecular mechanisms and clinical applications of angiogenesis. 2011 , 473, 298-307	3534
769	Targeting stem cell niches and trafficking for cardiovascular therapy. 2011 , 129, 62-81	37
768	Uncovering the role of hypoxia inducible factor-1 α in skin carcinogenesis. 2011 , 1816, 1-12	15
767	Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. <i>Cancer Cell</i> , 2011 , 19, 512-26	24.3 464
766	Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k α a single convergent point promoting tumor inflammation and progression. <i>Cancer Cell</i> , 2011 , 19, 715-27	24.3 291
765	CXCL12 (SDF1 α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. 2011 , 17, 2074-80	337

764	Circulation of progenitor cells in obese and lean colorectal cancer patients. 2011 , 20, 2461-8	58
763	Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. 2011 , 8, 241-54	75
762	Tumor microenvironment and progression. 2011 , 103, 468-74	120
761	Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. <i>Advanced Drug Delivery Reviews</i> , 2011 , 63, 582-96	18.5 99
760	Myeloid cell diversification and complexity: an old concept with new turns in oncology. 2011 , 30, 27-43	34
759	Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. 2011 , 30, 83-95	232
758	Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. 2011 , 103, 673-80	37
757	Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. 2011 , 104, 287-91	51
756	Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung. 2011 , 14, 125-33	11
755	Anastomotic leakage contributes to the risk for systemic recurrence in stage II colorectal cancer. 2011 , 15, 120-9	60
754	Endothelial progenitor cell biology in disease and tissue regeneration. 2011 , 4, 24	119
753	Tumor-initiating cells and tumor vascularization. 2011 , 56, 335-40	10
752	Concise review: Vascular stem cells and tumor angiogenesis. 2011 , 29, 163-8	45
751	Current concepts and management of glioblastoma. 2011 , 70, 9-21	319
750	S100B attenuates microglia activation in gliomas: possible role of STAT3 pathway. 2011 , 59, 486-98	57
749	The brain tumor microenvironment. 2011 , 59, 1169-80	355
748	Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. 2011 , 117, 4925-38	81
747	Circulating osteogenic cells: implications for injury, repair, and regeneration. 2011 , 26, 1685-93	68

746	Hypoxia-inducible factor-1 β protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. 2011 , 35, 579-84	52
745	Novel ultrasound and DCE-MRI analyses after antiangiogenic treatment with a selective VEGF receptor inhibitor. 2011 , 37, 909-21	7
744	Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. 2011 , 11, 1005-24	19
743	Anti-angiogenic therapy in uveal melanoma. 2012 , 49, 117-136	21
742	Role for circulating osteogenic precursor cells in aortic valvular disease. 2011 , 31, 2965-71	49
741	Combined blockade of integrin- $\alpha 4$ plus cytokines SDF-1 β or IL-1 β potently inhibits tumor inflammation and growth. 2011 , 71, 6965-75	81
740	VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. 2011 , 71, 4758-68	187
739	Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. 2011 , 17, 5226-32	74
738	Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. 2011 , 29, 2689-95	172
737	Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. 2011 , 2, 135-147	49
736	Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. 2011 , 17, 4872-81	50
735	Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. 2011 , 71, 19-28	163
734	Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. 2011 , 71, 6986-96	86
733	Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. 2011 , 71, 5512-21	48
732	Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. 2011 , 8, 393-404	215
731	CXCR4 as a Therapeutic Target. 2011 , 239-278	
730	The primary cilium as a biomarker in the hypoxic adaptation of bone marrow-derived mesenchymal stromal cells: a role for the secreted frizzled-related proteins. 2011 , 6, 107-18	24
729	An evolutionary explanation for the perturbation of the dynamics of metastatic tumors induced by surgery and acute inflammation. <i>Cancers</i> , 2011 , 3, 945-70	6.6 1

728	Resistance--the true face of biological defiance. 2012 , 51, 413-22		3
727	Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. 2012 , 2, 434-49		48
726	Tumor microenvironment in the brain. <i>Cancers</i> , 2012 , 4, 218-43	6.6	70
725	Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. 2012 , 32, 3018-32		167
724	Reply to J.W. Locasale et al. 2012 , 30, 338-339		78
723	Vinorelbine inhibits angiogenesis and 95D migration via reducing hypoxic fibroblast stromal cell-derived factor 1 secretion. 2012 , 237, 1045-55		7
722	Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. 2012 , 18, 2930-42		87
721	Targeting angiogenesis for treatment of NSCLC brain metastases. 2012 , 12, 289-99		16
720	HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGF β activation. 2012 , 13, 216-23		19
719	Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. 2012 , 12, 899-924		25
718	Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. 2012 , 72, 5198-208		145
717	The dual roles of homeobox genes in vascularization and wound healing. 2012 , 6, 457-70		50
716	Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. 2012 , 13, 504-15		66
715	Advances in Cancer Stem Cell Biology. 2012 ,		2
714	Influence of pre-analytical variables on VEGF gene expression and circulating protein concentrations. 2012 , 10, 454-61		14
713	Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. 2012 , 1, 1135-1145		44
712	A microRNA Link to Glioblastoma Heterogeneity. <i>Cancers</i> , 2012 , 4, 846-72	6.6	14
711	Bone marrow-derived mesenchymal stromal cells enhance chimeric vessel development driven by endothelial cell-coated microtissues. 2012 , 18, 285-94		38

710	Tie2-dependent knockout of HIF-1 impairs burn wound vascularization and homing of bone marrow-derived angiogenic cells. 2012 , 93, 162-9	25
709	CXCR4 inhibitors: tumor vasculature and therapeutic challenges. 2012 , 7, 251-64	45
708	Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. 2012 , 70, 361-70	51
707	Growth Regulation of Nervous System Tumours: Models for Assessment of Angiogenesis in Brain Tumours. 2012 , 181-200	
706	Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. 2012 , 14, 1379-92	161
705	Mechanisms of glioma-associated neovascularization. 2012 , 181, 1126-41	310
704	Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. 2012 , 18, 1207-13	151
703	Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. 2012 , 30, 4026-34	162
702	Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. 2012 , 318, 2417-26	120
701	Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. 2012 , 18, 771-82	129
700	Therapeutic targeting of VEGF in the treatment of glioblastoma. 2012 , 16, 973-84	30
699	Angiogenic inhibition in high-grade gliomas: past, present and future. 2012 , 12, 733-47	25
698	Immunohistochemical analysis of CD45RO+ T cells and vascular endothelial growth factor expression in cyclosporin A-induced rat gingival tissue. 2012 , 83, 248-55	1
697	Differential macrophage programming in the tumor microenvironment. 2012 , 33, 119-26	616
696	Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. 2012 , 21, 1247-66	43
695	Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence. 2012 , 11, 80	27
694	Characterization of iNOS(+) Neutrophil-like ring cell in tumor-bearing mice. 2012 , 10, 152	12
693	Macrophages and angiogenesis: a role for Wnt signaling. 2012 , 4, 13	58

692	Myeloid cells in tumor inflammation. 2012 , 4, 14	50
691	Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy. 2012 , 18, 4365-74	54
690	Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. 2012 , 35, 619-28	72
689	The Role of Bone Marrow-Derived Progenitor Cells in Tumor Growth and Angiogenesis. 2012 , 45-54	
688	Pseudoprogession and treatment effect. 2012 , 23, 277-87, viii-ix	22
687	Endothelial progenitor cells: current issues on characterization and challenging clinical applications. 2012 , 8, 926-39	41
686	Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). 2012 , 14, 564-74	11
685	The metastatic niche and stromal progression. 2012 , 31, 429-40	147
684	VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. 2012 , 120, 4653-62	215
683	Stem Cell Mobilization. 2012 ,	1
682	Stem Cells and Cancer Stem Cells, Volume 8. 2012 ,	3
681	Cellular host responses to gliomas. 2012 , 7, e35150	27
680	Suppression of glioma progression by EglN3. 2012 , 7, e40053	13
679	Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. 2012 , 7, e43339	106
678	Angiogenesis in head and neck cancer: a review of the literature. 2012 , 2012, 358472	20
677	Hypoxia promotes tumor growth in linking angiogenesis to immune escape. <i>Frontiers in Immunology</i> , 2012 , 3, 21	8.4 114
676	4.7 Rock, paper, and molecular scissors: regulating the game of extracellular matrix homeostasis, remodeling, and inflammation.	
675	Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. 2012 , 3, 1036-48	60

674	Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). 2012 , 72, 913-24		39
673	Emerging insights into the molecular and cellular basis of glioblastoma. 2012 , 26, 756-84		388
672	Long-term administration of AMD3100, an antagonist of SDF-1/CXCR4 signaling, alters fracture repair. 2012 , 30, 1853-9		55
671	Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF- β signaling pathway. 2012 , 189, 444-53		289
670	Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. 2012 , 69, 1391-414	34	
669	Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). 2012 , 5, 133-49		68
668	Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. 2012 , 167, 195-205		288
667	TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. <i>Cancer Cell</i> , 2012 , 21, 212-26	24.3	105
666	Accessories to the crime: functions of cells recruited to the tumor microenvironment. <i>Cancer Cell</i> , 2012 , 21, 309-22	24.3	2685
665	S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. <i>Cancer Cell</i> , 2012 , 21, 642-654	24.3	191
664	VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. <i>Cancer Cell</i> , 2012 , 22, 21-35	24.3	423
663	Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. 2012 , 10, 77-83		29
662	New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. 2012 , 1825, 29-36		257
661	Alternative origins of stroma in normal organs and disease. 2012 , 8, 312-23		51
660	Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. 2012 , 31, 16		114
659	Chemokine receptor CXCR7 mediates human endothelial progenitor cells survival, angiogenesis, but not proliferation. 2012 , 113, 1437-46		47
658	The brain tumor microenvironment. 2012 , 60, 502-14		261
657	New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis. 2012 , 95, 131-7		16

656	Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions. 2012 , 61, 409-24		24
655	Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-B/MMP-2 signaling pathways. 2013 , 11, 132		38
654	Stable tumor vessel normalization with pO ₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. 2013 , 91, 883-99		48
653	Mechanisms of resistance to anti-angiogenesis therapies. 2013 , 95, 1110-9		95
652	Do we really know why colorectal anastomoses leak?. 2013 , 17, 1698-707		149
651	Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche. 2013 , 1, 101-110		36
650	IL-17 mediates resistance to anti-VEGF therapy. 2013 , 19, 1092-4		21
649	Proliferating macrophages prevail in atherosclerosis. 2013 , 19, 1094-5		37
648	Inhibition of formyl peptide receptor in high-grade astrocytoma by Chemotaxis Inhibitory Protein of <i>S. aureus</i> . <i>British Journal of Cancer</i> , 2013 , 108, 587-96	8.7	18
647	Deciphering and reversing tumor immune suppression. 2013 , 39, 61-73		392
646	Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. 2013 , 19, 4392-403		131
645	Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas. 2013 , 23, 242-51		30
644	Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy. 2013 , 23, 281-7		27
643	Mechanisms of radiation-induced skin injury and implications for future clinical trials. 2013 , 89, 311-8		44
642	Hematopoietic stem and progenitor cell migration after hypofractionated radiation therapy in a murine model. 2013 , 87, 1162-70		7
641	Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. 2013 , 122, 4054-67		146
640	Microenvironmental regulation of tumor progression and metastasis. 2013 , 19, 1423-37		3959
639	NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells. <i>British Journal of Cancer</i> , 2013 , 109, 360-9	8.7	12

638	CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1/CXCR4 axis. 2013 , 12, 115		20
637	Disrupting the CXCL12/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma. 2013 , 13, 85		18
636	Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. 2013 , 6, 95		38
635	Circulating Osteogenic Cells. 2013 , 111-118		
634	Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. 2013 , 2, 49-65		95
633	History of myeloid-derived suppressor cells. 2013 , 13, 739-52		793
632	CXCR4(+) dendritic cells promote angiogenesis during embryo implantation in mice. 2013 , 16, 417-27		32
631	Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. 2013 , 85, 342-7		9
630	Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. <i>International Review of Cell and Molecular Biology</i> , 2013 , 301, 1-35	6	70
629	Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. 2013 , 32, 4057-63		155
628	Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. 2013 , 61, 25-41		145
627	A review on CXCR4/CXCL12 axis in oncology: no place to hide. 2013 , 49, 219-30		428
626	Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. 2013 , 139, 57-65		12
625	Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis. 2013 , 288, 4908-21		52
624	Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. 2013 , 86, 978-85		20
623	Issues to be considered when studying cancer in vitro. 2013 , 85, 95-111		10
622	Fibroblastos sinoviales. 2013 , 14, 121-128		2
621	S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. 2013 , 19, 3764-75		61

620	Targeting tumor-infiltrating macrophages to combat cancer. 2013 , 5, 1075-87	122
619	The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. 2013 , 260, 99-106	67
618	Anti-tumour strategies aiming to target tumour-associated macrophages. 2013 , 138, 93-104	185
617	The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. 2013 , 1830, 2496-508	117
616	Emerging Opportunities for Targeting the Tumor-Stroma Interactions for Increasing the Efficacy of Chemotherapy. 2013 , 53-86	
615	Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. 2013 , 91, 439-48	107
614	Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. 2013 , 153, 139-52	572
613	Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. 2013 , 7, 130-42	21
612	Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. 2013 , 48, 222-72	465
611	GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. 2013 , 15, 201-13	274
610	Macrophage biology in development, homeostasis and disease. 2013 , 496, 445-55	2521
609	The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. <i>Seminars in Cancer Biology</i> , 2013 , 23, 171-82	12.7 114
608	An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer. 2013 , 319, 1596-603	34
607	Ovarian cancer stem cells: working towards the root of stemness. 2013 , 338, 147-57	94
606	Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis. 2013 , 32, 3829-39	24
605	Neovascularization and hematopoietic stem cells. 2013 , 67, 235-45	17
604	Cancer Immunotherapy. 2013 , 198-214	1
603	Decoding the cancer stem cell hypothesis in glioblastoma. 2013 , 2, 319-30	20

602	Mesenchymal stem cell signaling in cancer progression. 2013 , 39, 180-8	81
601	Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. 2013 , 49, 231-44	41
600	Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells. 2013 , 56, 204-13	32
599	The Clinical Applications of Curcumin: Current State and the Future. 2013 , 19, 2011-2031	2
598	Oligomannururate sulfate inhibits CXCL12/SDF-1-mediated proliferation and invasion of human tumor cells in vitro. 2013 , 34, 1554-9	9
597	Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. 2013 , 19, 1773-83	160
596	HEXIM1 down-regulates hypoxia-inducible factor-1 β protein stability. 2013 , 456, 195-204	9
595	Opportunities and challenges for successful use of bevacizumab in pediatrics. 2013 , 3, 92	7
594	The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. 2013 , 4, 157	86
593	Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities. 2013 , 4, S129-35	24
592	Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. 2013 , 25, 313-24	31
591	Development and preclinical characterization of a humanized antibody targeting CXCL12. 2013 , 19, 4433-45	30
590	Angiogenic Signaling and Structural Abnormalities in Tumors. 2013 , 367-387	
589	Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. 2013 , 19, 1670-80	46
588	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. 2013 , 14, 2171-82	13
587	Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. 2013 , 6, 447-58	23
586	Endometriosis, a disease of the macrophage. <i>Frontiers in Immunology</i> , 2013 , 4, 9	8.4 157
585	Expression of CXCR4 is associated with progression and invasion in patients with nasal-surface basal cell carcinoma. 2013 , 75, 332-41	4

584	Vascular Targeting Approaches to Treat Cancer. 2013 , 59-95	2
583	Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. 2013 , 132, 2537-47	35
582	Harnessing the antitumor potential of macrophages for cancer immunotherapy. 2013 , 2, e26860	67
581	SOCS, inflammation, and cancer. 2013 , 2, e24053	113
580	Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis. 2013 , 32, 502-13	42
579	Hypoxia-mediated regulation of macrophage functions in pathophysiology. 2013 , 25, 67-75	58
578	Cell trafficking of endothelial progenitor cells in tumor progression. 2013 , 19, 3360-8	82
577	The role of tumor-associated macrophages in tumor vascularization. 2013 , 5, 20	76
576	New treatment strategies to eradicate cancer stem cells and niches in glioblastoma. 2013 , 53, 764-72	11
575	Obstructive sleep apnea and endothelial progenitor cells. 2013 , 7, 1077-90	11
574	Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. 2013 , 6, 217-22	12
573	Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. 2013 , 5, 1765-1770	7
572	PI3-kinase β promotes Rap1a-mediated activation of myeloid cell integrin $\alpha 1$, leading to tumor inflammation and growth. 2013 , 8, e60226	40
571	Berberine Targets AP-2/hTERT, NF- κ B/COX-2, HIF-1 α /VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. 2013 , 8, e69240	76
570	VEGF in tumor progression and targeted therapy. 2013 , 13, 423-43	65
569	A novel high-resolution in vivo imaging technique to study the dynamic response of intracranial structures to tumor growth and therapeutics. 2013 , e50363	8
568	A review of tasquinimod in the treatment of advanced prostate cancer. 2013 , 7, 167-74	9
567	Signal transduction in tumor angiogenesis. 861-871	

566	Brain Tumor Invasion and Angiogenesis. 2013,	1
565	Accessory Cells in Tumor Angiogenesis [Tumor-Associated Pericytes. 2013,	3
564	Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. 2014, 5, 75	350
563	Angiogenesis and antiangiogenic agents in cervical cancer. 2014, 7, 2237-48	44
562	Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. 2014, 7, 223-34	11
561	Antiangiogenesis therapy: an update after the first decade. 2014, 29, 1-11	43
560	Myeloid Derived Suppressor Cells: Fuel the Fire. 2014, 3, e123	10
559	Antiangiogenic therapies for glioblastoma. 2014, 3, 349-58	5
558	Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. 2014, 16, 771-88	161
557	Blocking SDF-1/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. 2014, 13, 483-91	31
556	Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma. 2014, 37, E8	31
555	Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. 2014, 6, 663-6	33
554	A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1 α and HIF2 α stability and tumor growth, angiogenesis, and metastasis. 2014, 12, 1520-31	86
553	Reciprocal Supportive Interplay between Glioblastoma and Tumor-Associated Macrophages. <i>Cancers</i> , 2014, 6, 723-40	6.6 21
552	Tumor-associated macrophages as major players in the tumor microenvironment. <i>Cancers</i> , 2014, 6, 1670-80	884
551	Resistance to antiangiogenic therapies. 2014, 10, 1417-25	9
550	Cells as delivery vehicles for cancer therapeutics. 2014, 5, 555-67	20
549	Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. 2014, 44, 639-50	44

548	Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor. 2014 , 203, W158-65	11
547	Antiangiogenic therapy for glioblastoma: current status and future prospects. 2014 , 20, 5612-9	92
546	The significance of macrophage phenotype in cancer and biomaterials. 2014 , 3, 62	20
545	Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. 2014 , 20, 644-57	41
544	Loss of endothelial-ARNT in adult mice contributes to dampened circulating proangiogenic cells and delayed wound healing. 2014 , 19, 429-41	2
543	VEGFR2-mediated vascular dilation as a mechanism of VEGF-induced anemia and bone marrow cell mobilization. 2014 , 9, 569-80	21
542	Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. 2014 , 3, e956579	42
541	Radiotherapy and the tumor stroma: the importance of dose and fractionation. 2014 , 4, 1	151
540	Role of endothelial progenitor cells in cancer progression. 2014 , 1846, 26-39	60
539	Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies. 2014 , 92, 38-48	10
538	HIF-1/MIF and NF- κ B/IL-6 axes contribute to the recruitment of CD11b+Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC. 2014 , 16, 168-79	40
537	Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. 2014 , 9, 47-71	672
536	Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. 2014 , 25, 1-19	198
535	CXCR4 as biomarker for radioresistant cancer stem cells. 2014 , 90, 687-99	59
534	Resistance to antiangiogenic therapy. 2014 , 14, 443	8
533	Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. 2014 , 116, 59-65	18
532	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. 2014 , 1845, 31-41	54
531	Neutrophils promote the malignant glioma phenotype through S100A4. 2014 , 20, 187-98	143

530	The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. 2014 , 66, 222-307	327
529	The Role of Tumor-Associated Macrophages (TAMs) in Tumor Progression. 2014 , 49-74	1
528	Tumor microenvironment and cellular stress: signaling, metabolism, imaging, and therapeutic targets. Preface. 2014 , 772, v-viii	22
527	Roles of tumor suppressors in regulating tumor-associated inflammation. 2014 , 21, 1677-86	39
526	Glioma Cell Biology. 2014 ,	2
525	Isolated limb infusion as a model to test new agents to treat metastatic melanoma. 2014 , 109, 357-65	7
524	Obesity, proinflammatory mediators, adipose tissue progenitors, and breast cancer. 2014 , 26, 545-50	13
523	RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. 2014 , 74, 7285-7297	82
522	Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. 2014 , 143, 512-9	202
521	Tumor-associated macrophages: from mechanisms to therapy. 2014 , 41, 49-61	2228
520	Post-treatment imaging changes in primary brain tumors. 2014 , 16, 397	26
519	Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. 2014 , 16, 543-61	97
518	Current status of antiangiogenic therapies for glioblastomas. 2014 , 23, 199-210	26
517	HIF transcription factors, inflammation, and immunity. 2014 , 41, 518-28	603
516	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. 2014 , 59, 1435-47	136
515	Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. 2014 , 63, 587-99	43
514	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 2014 , 32, 700-9	4
513	Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. 2014 , 119, 135-40	26

512	Cell-based therapy in lung regenerative medicine. 2014 , 2, 7	26
511	Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma. 2014 , 21, 1435-40	7
510	Novel target for peptide-based imaging and treatment of brain tumors. 2014 , 13, 996-1007	41
509	Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. 2014 , 135, 2569-78	76
508	Antiangiogenic therapies: going beyond their limits. 2014 , 4, 31-41	77
507	Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis. 2014 , 5, 5054	9
506	Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1 β /VEGF signaling axis. 2014 , 35, 2924-33	18
505	The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. 2014 , 343, 51-61	34
504	Molecular Mechanisms of Angiogenesis. 2014 ,	3
503	Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. 2014 , 33, 1743-54	154
502	Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice. 2014 , 33, 74-84	51
501	Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma. 2014 , 44, 600-8	2
500	Glioblastoma: Defining Tumor Niches. 2015 , 1, 252-265	213
499	MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. 2015 , 136, E602-13	79
498	Angiogenese beim malignen Melanom. 2015 , 13, 125-136	2
497	The Role of Angiogenesis in Cancer. 2015 , 64-71	4
496	1 Radiobiologyfundamentals ofRadiobiology of Radiosurgery. 2015 ,	
495	A Hypothesis for the Role of RECK in Angiogenesis. 2016 , 14, 106-15	16

494	HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model. 2014 , 22, 139-45	16
493	. 2015 ,	2
492	Common responses of tumors and wounds to hypoxia. 2015 , 21, 75-87	28
491	Inflammatory and Innate Immune Cells in Cancer Microenvironment and Progression. 2015 , 9-28	4
490	The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. 2015 , 40, 425-34	98
489	Adaptation to antiangiogenic therapy in neurological tumors. 2015 , 72, 3069-82	3
488	Matrix metalloproteinase-9 is essential for physiological Beta cell function and islet vascularization in adult mice. 2015 , 185, 1094-103	17
487	Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. 2015 , 34, 65	10
486	Emerging Applications for Optically Enabled Intravital Microscopic Imaging in Radiobiology. 2015 , 14, 7290.2015.00022	2
485	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. 2015 , 61, 1591-602	276
484	Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis. 2015 , 121, 591-8	13
483	Angiogenesis in malignant melanoma. 2015 , 13, 125-36	16
482	Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. 2015 , 17, 170-82	490
481	Collagen VI regulates peripheral nerve regeneration by modulating macrophage recruitment and polarization. 2015 , 129, 97-113	72
480	Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. 2015 , 11, 577-91	107
479	A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation. 2015 , 101, 38-47	12
478	The evolving roles of pericyte in early brain injury after subarachnoid hemorrhage. 2015 , 1623, 110-22	21
477	Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. 2015 , 44-46, 94-112	240

476	Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. <i>British Journal of Cancer</i> , 2015 , 112, 1199-205	8.7	34
475	Intertwined regulation of angiogenesis and immunity by myeloid cells. 2015 , 36, 240-9		86
474	The great escape; the hallmarks of resistance to antiangiogenic therapy. 2015 , 67, 441-61		140
473	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. 2015 , 36, 198-216		93
472	Macrophages and therapeutic resistance in cancer. <i>Cancer Cell</i> , 2015 , 27, 462-72	24.3	786
471	Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks. 2015 , 369, 416-26		39
470	Glioma Angiogenesis and Perfusion Imaging: Understanding the Relationship between Tumor Blood Volume and Leakiness with Increasing Glioma Grade. 2015 , 36, 2030-5		26
469	CCL9 Induced by TGF β Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. 2015 , 75, 5283-98		49
468	Integrative Mouse and Human Studies Implicate ANGPT1 and ZBTB7C as Susceptibility Genes to Ischemic Injury. 2015 , 46, 3514-22		12
467	Microenvironmental regulation of therapeutic response in cancer. 2015 , 25, 198-213		427
466	Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. 2015 , 1855, 1-16		44
465	Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. 2015 , 5, 168-81		55
464	Regulation of tumor metastasis by myeloid-derived suppressor cells. 2015 , 66, 97-110		310
463	Hypoxia-inducible factor-1alpha in hepatic fibrosis: A promising therapeutic target. 2015 , 108, 1-7		34
462	Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. 2015 , 121, 997-1007		61
461	Resistance to Kinase Inhibitors in Poorly Differentiated and Anaplastic Thyroid Cancer: Preclinical In vitro Evidences. 2016 , 5,		
460	Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma. 2016 , 8, 172-178		6
459	Modulation of Innate Immunity by Hypoxia. 2016 , 81-106		

458	Glioma Stem Cells: Signaling, Microenvironment, and Therapy. 2016 , 2016, 7849890	108
457	Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets. 2016 , 2016, 5728438	74
456	Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. 2016 , 2016, 6809105	92
455	Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells. 2016 , 17,	45
454	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. 2016 , 4, 27	83
453	The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis. 2016 , 17,	78
452	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. 2016 , 4,	187
451	Radiation-induced immune responses: mechanisms and therapeutic perspectives. 2016 , 51, 157-163	31
450	The Changes of HIF-1 α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. 2016 , 8, 297-302	52
449	GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. 2016 , 7, 79101-79116	29
448	Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. 2016 , 81, 21-29	4
447	MicroRNA-133a inhibits the malignant behavior of glioma via downregulation of matrix metalloproteinase 9. 2016 , 13, 3220-6	4
446	Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. 2016 , 2, 758-770	451
445	Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF- β Small Molecule Inhibitor. 2016 , 18, 795-805	24
444	The ever-expanding role of HIF in tumour and stromal biology. 2016 , 18, 356-65	241
443	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. 2016 , 18, 632-44	124
442	Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems?. 2016 , 1865, 147-54	6
441	A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). 2016 , 11, 643-653	30

440	Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. 2016 , 168, 98-112	77
439	Mutually Supportive Mechanisms of Inflammation and Vascular Remodeling. <i>International Review of Cell and Molecular Biology</i> , 2016 , 326, 201-78	6 15
438	Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab. 2016 , 8, 234-40	6
437	Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. 2016 , 17, 2445-2459	293
436	Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy. 2016 , 6, 30619	69
435	Cancer Stem Cells and Tumor-Associated Macrophages. 2016 , 367-394	1
434	CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. 2016 , 7, 11674	90
433	Enhanced angiogenesis, hypoxia and neutrophil recruitment during Myc-induced liver tumorigenesis in zebrafish. 2016 , 6, 31952	19
432	M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation. 2016 , 6, 27548	54
431	Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis. 2016 , 31, e229-34	23
430	HIF-1 at the crossroads of hypoxia, inflammation, and cancer. 2016 , 138, 1058-66	269
429	Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma. 2016 , 15, 607-16	10
428	Radiobiology of Glioblastoma. 2016 ,	2
427	Tumor Microenvironment, Hypoxia, and Stem Cell-Related Radiation Resistance. 2016 , 189-207	
426	Effect of Irradiation on Tumor Microenvironment and Bone Marrow Cell Migration in a Preclinical Tumor Model. 2016 , 96, 170-8	7
425	Hypoxia inducible factor 1 β A critical factor for the immune response to pathogens and Leishmania. 2016 , 309, 42-49	14
424	Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. 2016 , 22, 154-62	144
423	Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. 2016 , 13, 226-36	18

422	Therapeutic application of anti-angiogenic nanomaterials in cancers. 2016 , 8, 12444-70	95
421	Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. 2016 , 375, 349-359	56
420	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. 2016 , 130, 95-190	120
419	Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. 2016 , 2, 20-34	78
418	Tumor Microenvironment. 2016 , 1-10	1
417	Angiogenesis in melanoma: an update with a focus on current targeted therapies. 2016 , 69, 472-83	46
416	The Role of Microenvironment in the Control of Tumor Angiogenesis. 2016 ,	3
415	Significance and therapeutic implications of endothelial progenitor cells in angiogenic-mediated tumour metastasis. 2016 , 100, 177-89	17
414	Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. 2016 , 21, 281-2	27
413	Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. 2016 , 5, e1065370	5
412	The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. 2016 , 88, 222-236	13
411	Autophagy, a double-edged sword in anti-angiogenesis therapy. 2016 , 33, 10	44
410	Pharmacologic resistance in colorectal cancer: a review. 2016 , 8, 57-84	259
409	Curcumin and its promise as an anticancer drug: An analysis of its anticancer and antifungal effects in cancer and associated complications from invasive fungal infections. 2016 , 772, 33-42	59
408	New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk. 2016 , 113, 35-41	25
407	Hypoxia in astrocytic tumors and implications for therapy. 2016 , 85, 227-233	26
406	Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. 2017 , 36, 439-445	194
405	Differential propagation of stroma and cancer stem cells dictates tumorigenesis and multipotency. 2017 , 36, 570-584	34

404	VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. 2017 , 36, 1-12		24
403	Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery. <i>Advanced Drug Delivery Reviews</i> , 2017 , 109, 119-130	18.5	94
402	Angiogenic factors are increased in circulating granulocytes and CD34 cells of myeloproliferative neoplasms. 2017 , 56, 567-579		6
401	SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI. 2017 , 19, 1-7		34
400	Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model. <i>British Journal of Cancer</i> , 2017 , 116, 479-488	8.7	14
399	Different but synergistic effects of bone marrow-derived VEGFR2 and VEGFR2CD45 cells during hepatocellular carcinoma progression. 2017 , 13, 63-68		2
398	Antiangiogenic Therapy for Malignant Gliomas. 2017 , 163-175		
397	New Directions in Anti-Angiogenic Therapy for Glioblastoma. 2017 , 14, 321-332		71
396	Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology. 2017 , 102, 325-334		31
395	Tumor Microenvironment and Differential Responses to Therapy. 2017 , 7,		170
394	Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. 2017 , 67, 603-618		245
393	Tuning cancer fate: the unremitting role of host immunity. 2017 , 7,		25
392	Implications of neurovascular uncoupling in functional magnetic resonance imaging (fMRI) of brain tumors. 2017 , 37, 3475-3487		50
391	Fibronectin-adherent peripheral blood derived mononuclear cells as Paclitaxel carriers for glioblastoma treatment: An in vitro study. 2017 , 19, 721-734		8
390	Remodeling the Irradiated Tumor Microenvironment: The Fifth R of Radiobiology?. 2017 , 135-149		2
389	Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. 2017 , 19, 887-896		109
388	Response of the cerebral vasculature following traumatic brain injury. 2017 , 37, 2320-2339		129
387	Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation. 2017 , 39, 1010428317569100		

386	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. 2017 , 20, 185-204		309
385	Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. 2017 , 187, 940-953		45
384	TIE-2 expressing monocytes in human cancers. 2017 , 6, e1303585		27
383	RUNX1 Regulates Migration, Invasion, and Angiogenesis via p38 MAPK Pathway in Human Glioblastoma. 2017 , 37, 1243-1255		32
382	The network of immunosuppressive pathways in glioblastoma. 2017 , 130, 1-9		56
381	The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia. <i>Journal of Cellular Physiology</i> , 2017 , 232, 2312-2322	7	18
380	Canonical NFB signaling in myeloid cells is required for the glioblastoma growth. 2017 , 7, 13754		24
379	Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy. 2017 , 21, 591-603.e4		105
378	Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis. 2017 , 51, 1370-1382		16
377	Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. 2017 , 9, 1629-1645		40
376	Role of Tissue Factor-FVIIa Blood Coagulation Initiation Complex in Cancer. 2017 , 101-119		1
375	The peritoneum: healing, immunity, and diseases. 2017 , 243, 137-147		52
374	Regulation of Tumor Progression and Metastasis by Bone Marrow-Derived Microenvironments. 2017 , 303-328		
373	Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. 2017 , 14, 3529-3535		2
372	Upregulation of Wnt signaling under hypoxia promotes lung cancer progression. 2017 , 38, 1706-1714		18
371	Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. <i>Seminars in Cancer Biology</i> , 2017 , 47, 185-195	12.7	76
370	Loss of Caveolin-1 in Metastasis-Associated Macrophages Drives Lung Metastatic Growth through Increased Angiogenesis. 2017 , 21, 2842-2854		36
369	The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. 2017 , 39, 1010428317695528		32

368	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. 2017 , 23, 5745-5756	44
367	Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy. 2017 , 23, 1242-1249	39
366	Molecular targeting of hypoxia in radiotherapy. <i>Advanced Drug Delivery Reviews</i> , 2017 , 109, 45-62	18.5 92
365	Circulating CD14 HLA-DR myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. 2017 , 47, 1061-1071	42
364	Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1 β -mediated increase in E-selectin expression. 2017 , 140, 1370-1383	50
363	Increasing the Therapeutic Ratio of Radiotherapy. 2017 ,	1
362	The protective effect of curcumin in Olfactory Ensheathing Cells exposed to hypoxia. 2017 , 796, 62-68	14
361	Molecular Regulation of Sprouting Angiogenesis. 2017 , 8, 153-235	29
360	Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. 2017 , 18,	21
359	Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia. 2017 , 6,	42
358	The Pleiotropic Role of L1CAM in Tumor Vasculature. 2017 , 18,	10
357	Nanomedicine Strategies to Target Tumor-Associated Macrophages. 2017 , 18,	60
356	Barriers to Radiation-Induced Tumor Vaccination. <i>Frontiers in Immunology</i> , 2017 , 8, 229	8.4 111
355	The Microvascular Gap Junction Channel: A Route to Deliver MicroRNAs for Neurological Disease Treatment. 2017 , 10, 246	6
354	Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1 α and VEGF receptors. 2017 , 12, e0179202	25
353	Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenic factors and promote prostate cancer growth. 2017 , 17, 878	27
352	Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes. 2018 , 11, 406-415	16
351	Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway. 2018 , 101, 115-122	21

350	Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. 2018 , 78, 3220-3232	48
349	Resistance to Inhibitors of Angiogenesis. 2018 , 211-236	2
348	Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. 2018 , 245, 209-221	44
347	Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. 2018 , 20, 1356-1367	6
346	Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?. 2018 , 20, 14	18
345	Signaling Pathways Underlying Bone Metastasis: Hypoxia Signaling in Bone Metastasis and Beyond. 2018 , 4, 69-79	2
344	Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. 2018 , 96, 888-897	33
343	Redundant angiogenic signaling and tumor drug resistance. <i>Drug Resistance Updates</i> , 2018 , 36, 47-76	23.2 69
342	HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. 2018 , 115, E992-E1001	46
341	The hypoxic tumour microenvironment. 2018 , 7, 10	440
340	Phagocyte-extracellular matrix crosstalk empowers tumor development and dissemination. 2018 , 285, 734-751	25
339	Potential impact of invasive surgical procedures on primary tumor growth and metastasis. 2018 , 35, 319-331	65
338	Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. 2018 ,	1
337	Evaluation of Three-Dimensional Models to Study Tumor Angiogenesis. 2018 , 4, 337-346	10
336	Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension. 2018 , 58, 170-180	19
335	Developmentally regulated signaling pathways in glioma invasion. 2018 , 75, 385-402	48
334	The role of macrophage phenotype in regulating the response to radiation therapy. 2018 , 191, 64-80	37
333	Advances in immunotherapeutic research for glioma therapy. 2018 , 265, 741-756	45

- 332 OBSOLETE: Computational Systems Biology for the VEGF Family in Angiogenesis. **2018**,
- 331 Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. **2018**,
- 330 Anti-angiogenic Therapy-Mediated Endothelial Damage: A Driver of Breast Cancer Recurrence?. **2018**, 1100, 19-45 1
- 329 Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. *Frontiers in Immunology*, **2018**, 9, 2924 8.4 89
- 328 Hypoxia-induced endothelial cell responses - possible roles during periodontal disease. **2018**, 4, 241-248 17
- 327 Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer. *Frontiers in Immunology*, **2018**, 9, 3018 8.4 68
- 326 IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. **2018**, 9, 16462-16476 14
- 325 Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy. **2018**, 9, 1010 28
- 324 Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. **2018**, 38, 379-388 45
- 323 Restriction of drug transport by the tumor environment. **2018**, 150, 631-648 9
- 322 Ars2 promotes cell proliferation and tumorigenicity in glioblastoma through regulating miR-6798-3p. **2018**, 8, 15602 3
- 321 The vascular morphology of melanoma is related to Breslow index: An in vivo study with dynamic optical coherence tomography. **2018**, 27, 1280-1286 22
- 320 A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl. **2018**, 12, 12 24
- 319 The complement system in glioblastoma multiforme. **2018**, 6, 91 19
- 318 Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. **2018**, 20, 1494-1504 31
- 317 Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. **2018**, 24, 4643-4649 21
- 316 Immune Infiltration in Malignant Gliomas. **2018**, 359-374
- 315 S100B suppression alters polarization of infiltrating myeloid-derived cells in gliomas and inhibits tumor growth. **2018**, 439, 91-100 24

314	Role of Macrophages in Brain Tumor Growth and Progression. 2018 , 19,	57
313	Progress in the treatment of solid tumors with apatinib: a systematic review. 2018 , 11, 4137-4147	41
312	Targeting Macrophages in Cancer: From Bench to Bedside. 2018 , 8, 49	254
311	Hypoxic Signalling in Tumour Stroma. 2018 , 8, 189	32
310	Obstructive Sleep Apnea Monocytes Exhibit High Levels of Vascular Endothelial Growth Factor Secretion, Augmenting Tumor Progression. 2018 , 2018, 7373921	11
309	Computational Systems Biology for the VEGF Family in Angiogenesis. 2018 , 659-676	8
308	Glioblastoma niches: from the concept to the phenotypical reality. 2018 , 39, 1161-1168	24
307	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. 2018 , 11, 104	164
306	Synergy between peroxisome proliferator-activated receptor α agonist and radiotherapy in cancer. 2018 , 109, 2243-2255	8
305	The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. <i>Seminars in Cancer Biology</i> , 2018 , 52, 107-116	12.7 46
304	M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. 2019 , 11, 6125-6138	44
303	Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma. 2019 , 3, 47-65	31
302	The stimulation of thrombosis by hypoxia. 2019 , 181, 77-83	212
301	Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. 2019 , 237, 116952	41
300	Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma. 2019 , 68, 1959-1969	19
299	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. 2019 , 7,	20
298	Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. 2019 , 30, 917-936.e10	67
297	Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. 2019 , 21, 103	25

296	Controlling the Phenotype of Tumor-Infiltrating Macrophages via the PHD-HIF Axis Inhibits Tumor Growth in a Mouse Model. 2019 , 19, 940-954		11
295	MDSCs in pregnancy: Critical players for a balanced immune system at the feto-maternal interface. 2019 , 346, 103990		9
294	Tumors vs. Chronic Wounds: An Immune Cell's Perspective. <i>Frontiers in Immunology</i> , 2019 , 10, 2178	8.4	28
293	HIF Inhibitors: Status of Current Clinical Development. 2019 , 21, 6		135
292	Control of the Antitumor Immune Response by Cancer Metabolism. 2019 , 8,		27
291	Hypoxia and the Tumor Secretome. 2019 , 1136, 57-69		5
290	Hypoxia-Dependent Angiogenesis and Lymphangiogenesis in Cancer. 2019 , 1136, 71-85		31
289	Hypoxia Regulated Gene Network in Glioblastoma Has Special Algebraic Topology Structures and Revealed Communications Involving Warburg Effect and Immune Regulation. 2019 , 39, 1093-1114		1
288	Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages. 2019 , 116, 14254-14259		32
287	Identification and functional analysis of the Mandarin fish (<i>Siniperca chuatsi</i>) hypoxia-inducible factor-1 involved in the immune response. 2019 , 92, 141-150		14
286	Pericytes in Breast Cancer. 2019 , 1147, 93-107		7
285	Hypoxia and Cancer Metastasis. 2019 ,		3
284	Limitations of Anti-Angiogenic Treatment of Tumors. 2019 , 12, 981-986		45
283	Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?. 2019 , 79, 2447-2456		28
282	2-Oxonanonoid Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1 β . 2019 , 8,		2
281	The role of caveolin-1 in tumors of the brain - functional and clinical implications. 2019 , 42, 423-447		6
280	The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. <i>Cancers</i> , 2019 , 11,	6.6	22
279	Impact of proteolysis on cancer stem cell functions. 2019 , 166, 214-222		6

278	Collagen. 2019 ,	2
277	Tumorigenic Interplay Between Macrophages and Collagenous Matrix in the Tumor Microenvironment. 2019 , 1944, 203-220	8
276	The expanding family of noncanonical regulatory cell subsets. 2019 , 106, 369-383	4
275	Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. 2019 , 18, 63	139
274	Garcimultiflorone K inhibits angiogenesis through Akt/eNOS- and mTOR-dependent pathways in human endothelial progenitor cells. 2019 , 64, 152911	10
273	Assessment of Stabilization and Activity of the HIFs Important for Hypoxia-Induced Signalling in Cancer Cells. 2019 , 1928, 77-99	4
272	Vessel co-option in cancer. 2019 , 16, 469-493	158
271	Monocyte heterogeneity and functions in cancer. 2019 , 106, 309-322	153
270	Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. 2019 , 81, 535-560	24
269	Cancer Immunotherapy. 2019 , 231-250	
268	The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. 2019 , 8,	12
267	Mechanisms of Metastatic Tumor Dormancy and Implications for Cancer Therapy. 2019 , 20,	31
266	Glioblastoma: Microenvironment and Niche Concept. <i>Cancers</i> , 2018 , 11,	6.6 88
265	Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. 2019 , 8, e1515611	3
264	Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies. 2019 , 217, 34-40	13
263	Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. 2019 , 79, 795-806	109
262	Harnessing Macrophages for Vascularization in Tissue Engineering. 2019 , 47, 354-365	17
261	Getting TANned: How the tumor microenvironment drives neutrophil recruitment. 2019 , 105, 449-462	16

260	Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance. 2019 , 110, 3-12	27
259	CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. 2020 , 27, 669-679	8
258	Immunity, Hypoxia, and Metabolism—the Magic Trios of Cancer: Implications for Immunotherapy. 2020 , 100, 1-102	84
257	Hematopoietic Stem Cell Gene Therapy for Brain Metastases Using Myeloid Cell-Specific Gene Promoters. 2020 , 112, 617-627	7
256	Vessel co-option and resistance to anti-angiogenic therapy. 2020 , 23, 55-74	33
255	Molecular profiling of thymoma with myasthenia gravis: Risk factors of developing myasthenia gravis in thymoma patients. 2020 , 139, 157-164	7
254	Extracellular proteolysis in glioblastoma progression and therapeutics. 2020 , 1874, 188428	8
253	Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells. 2020 , 15, e0240533	5
252	Concepts of extracellular matrix remodelling in tumour progression and metastasis. 2020 , 11, 5120	317
251	Endothelial-Tumor Cell Interaction in Brain and CNS Malignancies. 2020 , 21,	8
250	IGFLR1 as a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates. 2020 , 7, 565173	3
249	Long non-coding RNA LUCAT1 up-regulates the expression of HIF-1 α and promotes the proliferation and metastasis of breast cancer cells via sponging miR-199a-5p. 2020 ,	
248	Research Progress and Existing Problems for Abscopal Effect. 2020 , 12, 6695-6706	3
247	ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer. 2020 , 80, 4668-4680	7
246	Local Delivery of Minocycline and Vorinostat Targets the Tumor Microenvironment to Inhibit the Recurrence of Glioma. 2020 , 13, 11397-11409	4
245	Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. 2020 , 12, 1995-2008	5
244	Tumor cell endogenous HIF-1 α activity induces aberrant angiogenesis and interacts with TRAF6 pathway required for colorectal cancer development. 2020 , 22, 745-758	3
243	Adult immuno-oncology: using past failures to inform the future. 2020 , 22, 1249-1261	8

242	Hypoxia: Turning vessels into vassals of cancer immunotolerance. 2020 , 487, 74-84		8
241	The enhanced treatment efficacy of invasive brain glioma by dual-targeted artemether plus paclitaxel micelles. 2020 , 48, 983-996		
240	Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma. 2020 , 11, 3015		34
239	Hypoxia in bone metastasis and osteolysis. 2020 , 489, 144-154		7
238	Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target. <i>Cancers</i> , 2020 , 12,	6.6	11
237	CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. 2020 , 159, 105010		22
236	Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. 2020 , 69, 1673-1697		19
235	Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. 2020 , 10, 221		94
234	Brain metastasis formation and irradiation by stereotactic radiation therapy combined with immunotherapy: A systematic review. 2020 , 149, 102923		9
233	Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. 2020 , 2020, 3415471		5
232	Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. 2020 , 2, vdaa031		2
231	Radiation-Enhanced Expression of CCL22 in Nasopharyngeal Carcinoma is Associated With CCR4 CD8 T Cell Recruitment. 2020 , 108, 126-139		8
230	Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis. 2020 , 9,		14
229	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. 2020 , 17, 807-821		232
228	A synthetic coumarin derivative (4-flourophénylacétamide-acétyl coumarin) impedes cell cycle at G0/G1 stage, induces apoptosis, and inhibits metastasis via ROS-mediated p53 and AKT signaling pathways in A549 cells. 2020 , 34, e22553		8
227	Tumor Microenvironment. 2020 ,		
226	Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. 2019 , 6, 160		264
225	Glioblastome Multiforme: A Bibliometric Analysis. 2020 , 136, 270-282		20

224	Atlas of Clinical Cases on Brain Tumor Imaging. 2020 ,		1
223	Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. 2020 , 31, 107568		7
222	Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	1
221	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. 2020 , 86, 102015		75
220	The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment. <i>Frontiers in Immunology</i> , 2020 , 11, 737	8.4	38
219	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020 , 12,	6.6	9
218	An update on angiogenesis targeting in head and neck squamous cell carcinoma. 2020 , 5, 5		11
217	Targeting tumor-associated macrophages in head and neck squamous cell carcinoma. 2020 , 106, 104723		12
216	Anti-angiogenic therapies in the management of glioblastoma. 2021 , 10, 37		5
215	HIF/Ca/NO/ROS is critical in roxadustat treating bone fracture by stimulating the proliferation and migration of BMSCs. 2021 , 264, 118684		4
214	Stromal metalloproteinases: Crucial contributors to the tumor microenvironment. 2021 , 71, 1-14		10
213	Tumor microenvironment. 2021 , 1-10		0
212	CCL2 in the Tumor Microenvironment. 2021 , 1302, 1-14		7
211	Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. 2021 , 9,		13
210	Sirtuin signaling in hematologic malignancies. 2021 , 233-258		
209	Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment. 2021 , 45, 1171-1181		11
208	Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma. 2021 , 41-63		
207	Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas. 2021 , 81, 2142-2156		7

206	Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study. 2021 , 16, e0246646		8
205	Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect. 2021 , 11,		22
204	Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021 , 12, 639636	8.4	10
203	The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy. 2021 , 10,		4
202	Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted on Melanoma. 2021 , 11, 597503		2
201	A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression. 2021 , 40, 477-500		1
200	Targeting macrophages in cancer immunotherapy. 2021 , 6, 127		65
199	In-Depth Characterization of Stromal Cells within the Tumor Microenvironment Yields Novel Therapeutic Targets. <i>Cancers</i> , 2021 , 13,	6.6	4
198	Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors. 2021 , 36, 73-83		11
197	Linking Serine/Glycine Metabolism to Radiotherapy Resistance. <i>Cancers</i> , 2021 , 13,	6.6	4
196	Anti-oncogenic activities exhibited by paracrine factors of MSCs can be mediated by modulation of and genes in glioma SCs. 2021 , 20, 147-165		1
195	Alternative Vascularization Mechanisms in Tumor Resistance to Therapy. <i>Cancers</i> , 2021 , 13,	6.6	5
194	Selinexor decreases HIF-1 α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity. 2021 , 147, 2025-2033		0
193	Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth. 2021 , 12, 823-844		0
192	Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?. 2021 , 125, 1-28		9
191	Endothelial Extracellular Vesicles: From Keepers of Health to Messengers of Disease. 2021 , 22,		15
190	Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution. 2021 , 15, 551-561		9
189	Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment. 2021 , 22,		7

188	Role of CXCR4 in the progression and therapy of acute leukaemia. 2021 , 54, e13076		6
187	Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer. 2021 , 81, 4110-4123		5
186	Delivery of siHIF-1 α to Reconstruct Tumor Normoxic Microenvironment for Effective Chemotherapeutic and Photodynamic Anticancer Treatments. 2021 , 17, e2100609		4
185	The prospects of nanotherapeutic approaches for targeting tumor-associated macrophages in oral cancer. 2021 , 34, 102371		1
184	ETIOLOGY AND PATHOGENESIS OF HYPOPHARYNX CANCER: GENETIC AND IMMUNOLOGICAL FACTORS OF DEVELOPMENT. Review. 2021 , 17, 102-113		
183	Fibroblasts and macrophages: Collaborators in tissue homeostasis. 2021 , 302, 86-103		6
182	Perspectives on Hypoxia Signaling in Tumor Stroma. <i>Cancers</i> , 2021 , 13,	6.6	3
181	Tumor Vessels Fuel the Fire in Glioblastoma. 2021 , 22,		5
180	Therapeutic targeting of the hypoxic tumour microenvironment. 2021 , 18, 751-772		32
179	Multimodal Role of PACAP in Glioblastoma. 2021 , 11,		2
178	Consequences of Extracellular Matrix Remodeling in Headway and Metastasis of Cancer along with Novel Immunotherapies: A Great Promise for Future Endeavor. 2021 ,		0
177	Heterogeneous Myeloid Cells in Tumors. <i>Cancers</i> , 2021 , 13,	6.6	2
176	The Renin-Angiotensin System in the Tumor Microenvironment of Glioblastoma. <i>Cancers</i> , 2021 , 13,	6.6	3
175	CXCR4 protects bone marrow-derived endothelial progenitor cells against hypoxia through the PI3K/Akt signaling pathway. 2021 , 22, 1200		1
174	Hydroxyethyl chitosan hydrogels for enhancing breast cancer cell tumorigenesis. 2021 , 184, 768-775		2
173	Circulating erythroblast abnormality associated with systemic pathologies may indicate bone marrow damage. 2021 , 10, 14-19		0
172	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. 2021 , 107986		2
171	Loss of Von Hippel-Lindau () Tumor Suppressor Gene Function: -HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). 2021 , 22,		7

170	The impact of microRNAs on myeloid-derived suppressor cells in cancer. 2021 , 82, 668-678	2
169	Macrophages induce inflammation by efferocytosis of apoptotic prostate cancer cells via HIF-1 β stabilization.	
168	Advance of nano anticancer therapies targeted on tumor-associated macrophages. 2021 , 446, 214126	2
167	Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer. 2022 , 409-435	1
166	Hypoxia and the phenomenon of immune exclusion. 2021 , 19, 9	20
165	Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. 2021 , 6, 12	18
164	Antiangiogenic Strategies for the Treatment of Gliomas. 2010 , 243-263	2
163	Role of Pericytes in Resistance to Antiangiogenic Therapy. 2010 , 311-323	1
162	Regulation of Angiogenesis by Hypoxia-Inducible Factors. 2013 , 93-106	2
161	Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. 2014 , 772, 83-99	10
160	Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease. 2011 , 447-495	1
159	Progenitor cell mobilization from extramedullary organs. 2012 , 904, 243-52	11
158	Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. 2020 , 1224, 117-140	50
157	Endothelial Progenitors in the Tumor Microenvironment. 2020 , 1263, 85-115	3
156	Implications of CXCR4/CXCL12 Interaction for Cancer Stem Cell Maintenance and Cancer Progression. 2015 , 89-130	2
155	Mechanisms of Tumor Angiogenesis. 2019 , 3-31	2
154	Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients?. 2010 , 133-157	2
153	Matrix Metalloproteinases (MMPs) in Cancer Initiation and Progression. 2017 , 207-236	1

152	VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment. 2017 , 96, 2103-2112		13
151	Angiogenesis and Brain Tumors. 2011 , 1151-1171		1
150	Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression. 2019 , 40, 118-134		27
149	The critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment.		5
148	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. 2019 , 4,		95
147	Hypoxia-inducible factors and innate immunity in liver cancer. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5052-5062	15.9	32
146	Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1151-64	15.9	363
145	Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. <i>Journal of Clinical Investigation</i> , 2010 , 120, 694-705	15.9	591
144	Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-1 α isoforms and promotes angiogenesis. <i>Journal of Clinical Investigation</i> , 2010 , 120, 4141-54	15.9	336
143	Adenovirus-mediated HIF-1 β gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2336-49	15.9	80
142	Heparan sulfate sulfatase SULF2 regulates PDGFR β signaling and growth in human and mouse malignant glioma. <i>Journal of Clinical Investigation</i> , 2012 , 122, 911-22	15.9	71
141	Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. <i>Journal of Clinical Investigation</i> , 2013 , 123, 189-205	15.9	140
140	The impact of hypoxia on tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3672-3679	15.9	250
139	Hypoxia-inducible factors: a central link between inflammation and cancer. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3689-3698	15.9	105
138	A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. <i>Journal of Clinical Investigation</i> , 2017 , 127, 1826-1838	15.9	22
137	A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. 2011 , 6, e21768		81
136	Improved culture-based isolation of differentiating endothelial progenitor cells from mouse bone marrow mononuclear cells. 2011 , 6, e28639		27
135	Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density. 2013 , 8, e72655		20

134	c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomas. 2013 , 8, e75436	16
133	Astrocytes directly influence tumor cell invasion and metastasis in vivo. 2013 , 8, e80933	57
132	Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. 2014 , 9, e98623	62
131	Endogenous brain pericytes are widely activated and contribute to mouse glioma microvasculature. 2015 , 10, e0123553	33
130	Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizyosity in Different Mouse Bone Marrow Compartments. 2016 , 11, e0158649	3
129	PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro. 2017 , 12, e0174968	17
128	Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. 2017 , 12, e0188116	4
127	Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies. 2017 , 32, 917-928	24
126	Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. 2013 , e71-e78	2
125	Glioblastoma: To Target the Tumor Cell or the Microenvironment?. 315-340	21
124	Class A1 scavenger receptor modulates glioma progression by regulating M2-like tumor-associated macrophage polarization. 2016 , 7, 50099-50116	16
123	Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane. 2017 , 8, 35877-35889	25
122	Dose dependent effects of cadmium on tumor angiogenesis. 2017 , 8, 44944-44959	25
121	Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. 2014 , 5, 481-92	44
120	HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1 α and HIF-2 β balance in renal cell carcinoma. 2017 , 8, 49713-49724	10
119	Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer. 2017 , 8, 68270-68279	2
118	"Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. 2017 , 8, 103890-103899	10
117	Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. 2014 , 5, 11283-96	99

116	Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy. 2014 , 5, 6353-64	25
115	Neoplastic cells are a rare component in human glioblastoma microvasculature. 2012 , 3, 98-106	65
114	Modulation of cerebral endothelial cell function by TGF- β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. 2015 , 6, 22480-95	42
113	EMMPRIN regulates tumor growth and metastasis by recruiting bone marrow-derived cells through paracrine signaling of SDF-1 and VEGF. 2015 , 6, 32575-85	25
112	Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions. 2016 , 7, 15444-59	35
111	Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. 2016 , 7, 16146-57	22
110	Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer. 2019 , 19, 138-151	18
109	Evaluation of VEGF, FGF and PDGF and Serum Levels of Inflammatory Cytokines in Patients with Glioma and Meningioma in Southern Iran. 2019 , 20, 2883-2890	8
108	Stromal-cell-derived Factor 1 β Promotes Tumor Progression in Colorectal Cancer. 2012 , 28, 27-34	2
107	Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma. 2010 , 16, 5642-6	21
106	Targeting tumor-associated macrophages in the tumor microenvironment. 2020 , 20, 234	25
105	Molecular mechanisms involved in tumor repopulation after radiotherapy. 2013 , 2, 442-448	17
104	Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance. 2017 , 22, 117	36
103	Interplay Between Metabolism and Oncogenic Process: Role of microRNAs. 2015 , 7, 11-27	34
102	Inhibition of PI3 Kinase Gamma Enzyme by Novel Phenylpyrazoles. 2013 , 34, 2829-2832	2
101	Microarray analysis of the hypoxia-induced gene expression profile in malignant C6 glioma cells. 2012 , 13, 4793-9	14
100	Malignant Transformation in Glioma Steered by an Angiogenic Switch: Defining a Role for Bone Marrow-Derived Cells. 2016 , 8, e471	9
99	Bone Marrow-Derived Cells in GBM Neovascularization. 2009 , 749-773	1

98 Chemokines and Primary Brain Tumors. **2010**, 253-270

97 The Pro-inflammatory Milieu and Its Role in Malignant Epithelial Initiation. **2010**, 409-430

96 Cancer Therapy by Targeting Vascular Endothelial Cell Growth Factor- and Non-Vascular Endothelial Cell Growth Factor-Mediated Angiogenesis. **2010**, 95-113

95 Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma. *Japanese Journal of Neurosurgery*, **2010**, 19, 758-766

94 Establishing the Tumor Microenvironment. 7-33

93 Malignant Glioma Patients: Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, Bevacizumab. **2011**, 277-290

92 Immunomodulatory Functions of Cancer Stem Cells. **2012**, 301-332

91 Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma. **2012**, 135-160

90 Vascular Stem Cells in Regulation of Angiogenesis. **2013**, 123-138

89 MET Inhibitors. **2013**, 209-234

88 Vascular Modulatory Functions of Macrophages. **2014**, 131-168

87 Progenitor Endothelial Cells as Biomarkers of Anti-vascular Agents. **2014**, 445-460

86 Glioma-Associated Proteases. **2014**, 317-395

85 Cellular Plasticity, Cancer Stem Cells and Metastasis. **2015**, 13-66

84 Tumour Angiogenesis. **2015**, 47-62

83 Kringle 1-5 Reduces Growth of Malignant Gliomas in Rats. **2015**, 25-34

82 Mechanisms of Tumor Angiogenesis. **2016**, 1-29

81 Correlation of an *in vivo* Model with Clinical Application of an Epigenetic Modifier, Inhibiting Tumor Growth and Metastasis, in Resistant Cholangiocarcinoma: A Case Study. **2016**, 07, 50-54

80	[Impact of preoperative drug therapy on the expression of angiogenesis markers in colorectal liver metastases]. 2017 , 79, 36-42		0
79	Proteolytic Networks at the Crossroads of Cancer Cell Life and Death: Cancer Stem Cell Deciding Cell Fate. 2017 , 237-263		
78	Refractory Mechanisms. 2017 , 351-367		
77	Vascular Stem Cells in Regulation of Angiogenesis. 2017 , 59-74		
76	The Value of Anti-angiogenics in Brain Tumor Therapy. 2018 , 1-18		
75	Problem and Handling of Anti-angiogenic Therapy for Glioblastoma : Vessel Co-option and Vascular Mimicry. <i>Japanese Journal of Neurosurgery</i> , 2018 , 27, 723-735		0
74	Angiogenesis and Anti-angiogenic Therapy in Head and Neck Cancer. <i>Current Cancer Research</i> , 2018 , 439-467		0.2
73	New Pericytes in the Adult Brain Originate from a Previously Unrecognized Pericyte Precursor. <i>SSRN Electronic Journal</i> ,		1
72	The Value of Anti-angiogenics in Primary Brain Tumor Therapy. 2018 , 1-18		
71	M2-polarized macrophages contribute to neovasculogenesis, leading to recurrence of oral cancer after radiation. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2018 , 64, 307-320		0.1
70	Selected factors influencing angiogenesis and hematopoietic niche. <i>Acta Haematologica Polonica</i> , 2018 , 49, 112-120		0.4 1
69	Tumour Angiogenesis. 2019 , 55-76		
68	The Value of Anti-angiogenics in Primary Brain Tumor Therapy. 2019 , 609-625		
67	Gene Expression Signature and Molecular Mechanism of Redox Homeostasis in Colorectal Cancer.		
66	Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment. <i>Cancers</i> , 2021 , 13,		6.6 0
65	Diffusion, Perfusion, and PET Imaging of Brain Tumors. 2020 , 41-47		
64	Hypoxia and Metastatic Disease. 2020 , 243-253		
63	Clinical Significance of C-X-C Motif Chemokine Receptor 4 and Integrin $\alpha 8$ Expression in Breast Cancer. <i>Journal of Breast Cancer</i> , 2020 , 23, 171-181		3 1

62	Changes in the tumor microenvironment and treatment outcome in glioblastoma: A pilot study.		
61	The genetic status of IDH1/2 and EGFR dictates the vascular landscape and the progression of gliomas.		
60	Stromal cell-derived factors in Duchenne muscular dystrophy. <i>Acta Myologica</i> , 2010 , 29, 398-403	1.6	5
59	Bevacizumab and intraocular tumors: an intriguing paradox. <i>Molecular Vision</i> , 2012 , 18, 2454-67	2.3	21
58	Molecular MRI differentiation of VEGF receptor-2 levels in C6 and RG2 glioma models. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 3, 300-11	2.2	11
57	Effects of NF- κ B and hypoxia on the biological behavior of Y79 retinoblastoma cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 1725-30	1.4	4
56	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015 , 5, 3376-88	4.4	6
55	Recruitment of monocytes and epigenetic silencing of intratumoral CYP7B1 primarily contribute to the accumulation of 27-hydroxycholesterol in breast cancer. <i>American Journal of Cancer Research</i> , 2019 , 9, 2194-2208	4.4	8
54	The roles and functions of macrophages in endometriosis. 2022 , 133-151		
53	Hypoxia as a driver of resistance to immunotherapy. <i>Drug Resistance Updates</i> , 2021 , 100787	23.2	8
52	Uncovering a Key Role of ETS1 on Vascular Abnormality in Glioblastoma. <i>Pathology and Oncology Research</i> , 2021 , 27, 1609997	2.6	0
51	Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2021 ,	7	2
50	Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment.. <i>Cancers</i> , 2022 , 14,	6.6	1
49	Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 60	7.8	5
48	Role of macrophages in tumor development. 2022 , 113-164		
47	Metabolism in tumor-associated macrophages.. <i>International Review of Cell and Molecular Biology</i> , 2022 , 367, 65-100	6	1
46	Role of Tumour-Associated Macrophages in Colon Cancer Progression and Its Therapeutic Targeting. 2022 , 193-215		
45	The Impact of Obesity, Adipose Tissue, and Tumor Microenvironment on Macrophage Polarization and Metastasis.. <i>Biology</i> , 2022 , 11,	4.9	1

44	Development and Validation of a Nomogram for Predicting Postoperative Distant Metastasis in Patients with Cervical Cancer.. <i>Medical Science Monitor</i> , 2022 , 28, e933379	3.2	0
43	Glioblastoma Vasculature: From its Critical Role in Tumor Survival to Relevant in Vitro Modelling. 2022 , 2,		0
42	Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers.. <i>Seminars in Cancer Biology</i> , 2022 ,	12.7	3
41	Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.. <i>Neuroscience</i> , 2022 ,	3.9	1
40	Intratumoural haematopoietic stem and progenitor cell differentiation into M2 macrophages facilitates the regrowth of solid tumours after radiation therapy.. <i>British Journal of Cancer</i> , 2021 ,	8.7	0
39	Tumour-associated macrophages heterogeneity drives resistance to clinical therapy.. <i>Expert Reviews in Molecular Medicine</i> , 2022 , 24, e17	6.7	2
38	Table_1.DOCX. 2020 ,		
37	The Multimodal Ultrasound Features of Ovarian Serous Surface Papillary Borderline Tumor. <i>Women S Health Reports</i> , 2022 , 3, 523-532	0.5	
36	Therapy-induced shaping of the glioblastoma microenvironment: Macrophages at play.. <i>Seminars in Cancer Biology</i> , 2022 ,	12.7	1
35	The Vascular Microenvironment in Glioblastoma: A Comprehensive Review. <i>Biomedicines</i> , 2022 , 10, 12854.8		0
34	Hypoxia-inducible factors: cancer progression and clinical translation. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	10
33	Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularization.		
32	Estrogen receptor signaling in the immune system. <i>Endocrine Reviews</i> ,	27.2	2
31	The Danse Macabre: Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes. <i>Frontiers in Immunology</i> , 13,	8.4	0
30	Regulation of Tumor Progression and Metastasis by Bone Marrow-Derived Microenvironments. 2022 , 245-266		
29	Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment. <i>Advanced Drug Delivery Reviews</i> , 2022 , 188, 114415	18.5	1
28	Pump proton inhibitors display anti-tumour potential in glioma.		
27	Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.		1

26	Targeting HIF-1 β by Natural and Synthetic Compounds: A Promising Approach for Anti-Cancer Therapeutics Development. 2022 , 27, 5192	1
25	The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies. 13,	0
24	B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis. 13,	
23	Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy. 13,	1
22	Introduction: Cancer a Global Challenge and Role of Angiogenesis in Cancer. 2022 , 1-9	0
21	Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis.	0
20	The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. 12,	0
19	Synergy of Polydopamine Nanovaccine and Endostar Alginate Hydrogel for Improving Antitumor Immune Responses Against Colon Tumor. Volume 17, 4791-4805	0
18	Antineoplastic agents in chemotherapy facilitating tumor growth and angiogenesis in the interval administrations. 2022 , 310, 121089	0
17	The Tumor Microenvironment. 2022 , 1-49	0
16	Siglec10: An immunosuppressor and negative predictor of survival prognosis in gliomas. 13,	0
15	The diagnostic and prognostic potential of the EGFR/MUC4/MMP9 axis in glioma patients. 2022 , 12,	0
14	Tumor immunomodulatory effects of polyphenols. 13,	0
13	The Study of the Extracellular Matrix in Chronic Inflammation: A Way to Prevent Cancer Initiation?. 2022 , 14, 5903	1
12	Cancer immunosurveillance in respiratory diseases. 2022 , 1-14	0
11	Bone Marrow Macrophages Induce Inflammation by Efferocytosis of Apoptotic Prostate Cancer Cells via HIF-1 β Stabilization. 2022 , 11, 3712	0
10	Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis.	1
9	WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.	0

- 8 A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. **2023**, 40, ○
- 7 Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma. **2023**, 15, 830 1
- 6 Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. **2023**, 22, 153303382211505 ○
- 5 Tumor immunology. **2023**, 245-452 ○
- 4 Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors. **2023**, 27-63 ○
- 3 Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. **2023**, 11, 718 ○
- 2 Development of a coupled modeling for tumor growth, angiogenesis, oxygen delivery, and phenotypic heterogeneity. ○
- 1 Hypoxia and the Metastatic Cascade. **2023**, 181-216 ○